keine Finanzberatung

DHR · Danaher Corporation

Life-sciences & diagnostics conglomerate

Risiko 3/10 · LOW-MODERATE RISK · life-sciences compounder · $207.66 ▼ 1.60%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $207.66
  • Market cap $146.0B
  • P/E (ttm) 37.02
  • Div yield 0.77%
  • 52-wk range $160.93 – $242.80
  • Index rank #87 / —

Wichtigste Risiken

  • Bioprocessing recovery stalls (Shareholders) — MED
  • Premium multiple on mid-single-digit growth (Shareholders) — MED
  • China and academic-funding exposure (Shareholders) — MED
  • CEO transition breaks the playbook (Shareholders) — LOW

Fazit

High-quality compounder in recovery mode; paying up for quality works here as long as bioprocessing keeps healing.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.